BREAKING NEWS: Meta-Analysis Finds Increased Risk of MI with Rosiglitazone (Avandia)
CLEVELAND -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.
CLEVELAND, May 21 -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
